NCT05537883View on ClinicalTrials.gov

Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

December 7, 2023

Study Completion Date

December 7, 2023

Conditions
Morbid ObesityBariatric Surgery Candidate
Interventions
DRUG

Liposomal bupivacaine

Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine

DRUG

Bupivacaine Injection

Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER